BAR­DA boosts the fight against an­tibi­ot­ic-re­sis­tant in­fec­tions with $144M awards

In a first, BAR­DA has of­fered a $76.9 mil­lion award to fund a mi­cro­bio­me-based ther­a­py’s last dash to­ward the FDA while promis­ing $77 mil­lion for a late-stage pro­gram com­bin­ing CRISPR tech and bac­te­rio­phages.

Both drugs are de­signed to ad­dress an­tibi­ot­ic-re­sis­tant in­fec­tions, with Vedan­ta’s VE303 aimed at C. dif­fi­cile in­fec­tions and Lo­cus Bio­sciences’ LBP-EC01 in­tend­ed to treat re­cur­rent UTIs caused by E. coli.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER